While combinations of EGFR and HDAC inhibitors have been reported, CUDC-101 is efficient as a single agent in several preclinical cancer models including anaplastic thyroid cancer, erlotinib-resistant glioblastoma, and lung, colon and breast cancers [35]. The gene discussed is HDAC9; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.